Business Description
Plus Therapeutics Inc
NAICS : 339112
SIC : 3841
ISIN : US23283K4022
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.05 | |||||
Equity-to-Asset | -0.12 | |||||
Debt-to-Equity | -3.1 | |||||
Debt-to-EBITDA | -0.34 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 44.5 | |||||
3-Year EPS without NRI Growth Rate | 51 | |||||
3-Year FCF Growth Rate | 48.5 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 29 | |||||
9-Day RSI | 34.87 | |||||
14-Day RSI | 39.73 | |||||
6-1 Month Momentum % | 63.49 | |||||
12-1 Month Momentum % | -53.25 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.92 | |||||
Quick Ratio | 0.92 | |||||
Cash Ratio | 0.8 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -114.6 | |||||
Shareholder Yield % | -58.16 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -509.92 | |||||
ROA % | -84.96 | |||||
ROIC % | -213.25 | |||||
ROC (Joel Greenblatt) % | -942.86 | |||||
ROCE % | -306.82 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | -0.2 | |||||
EV-to-EBITDA | -0.21 | |||||
EV-to-Forward-EBITDA | -0.27 | |||||
EV-to-Forward-Revenue | 0.8 | |||||
EV-to-FCF | -0.21 | |||||
Earnings Yield (Greenblatt) % | -502.51 | |||||
FCF Yield % | -187.62 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Plus Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -4.085 | ||
Beta | 0.44 | ||
Volatility % | 95.58 | ||
14-Day RSI | 39.73 | ||
14-Day ATR (€) | 0.042383 | ||
20-Day SMA (€) | 1.6673 | ||
12-1 Month Momentum % | -53.25 | ||
52-Week Range (€) | 0.94 - 4.415 | ||
Shares Outstanding (Mil) | 4.35 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Plus Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Plus Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Plus Therapeutics Inc Frequently Asked Questions
What is Plus Therapeutics Inc(FRA:XMP0)'s stock price today?
When is next earnings date of Plus Therapeutics Inc(FRA:XMP0)?
Does Plus Therapeutics Inc(FRA:XMP0) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |